Explore Stanford technologies available for licensing:

Stanford researchers in the Wu Lab have developed hypoallergenic and immunogenic induced pluripotent stem cells that could be used as a cancer treatment or prophylactic.

Stanford researchers have created a novel wearable device and system to assess fatigue on the user based on electrical activity associated with an eye blink of the subject.

Stanford researchers have developed a single-cell technology for a targeted high-throughput multiomic readout of RNA and gDNA.

Researchers at Stanford have developed a potent, insulin-based, insulin receptor antagonist that could be used as a hyperinsulinism therapeutic.

This invention is an innovative breakthrough in cancer radiotherapy, offering a cutting-edge solution to address the challenges of radio-resistant and immunosuppressive tumors.

Based on their proprietary HyTEC tissue engineering platform, researchers at Stanford have developed an osteoinductive intramedullary implant (IM) device for improved bone healing.

Researchers at Stanford have developed a porous biologics-loaded multimaterial construct, called Hybrid Tissue Engineering Construct (HyTEC), with applications in regenerative medicine and therapeutic delivery.

Technology Reference
CZ Biohub SF ref. no. CZB-231S
Stanford ref. no. S21-400

Researchers at Stanford have developed a new microparticle vaccine scaffold for the development of immunogenic subunit vaccines.

Technology Reference
CZ Biohub SF ref. no. CZB-230S
Stanford ref. no. S21-394

Stanford researchers have developed chemically modified AAV vectors through an unnatural amino acid substitution on the capsid surface for post-production vector engineering through biorthogonal copper-free click chemistry.

Stanford inventors have developed an early-stage screening method to diagnose abdominal aortic aneurysms (AAA). AAA is a common cardiovascular disease with high prevalence in European men 65 years and above.

Background

Technology Reference
CZB-213S
Stanford ref. no. S21-152

Researchers at CZ Biohub SF and Stanford have developed unique fusion proteins that have broad therapeutic benefits for the treatment of infection by existing and future coronaviruses.

Technology Reference
CZ Biohub ref. no. CZB-221S
Stanford ref. no. S21-272

Researchers at Stanford have developed a new therapeutic avenue for the treatment of RNA viral infections.

Technology Reference
CZ Biohub ref. no. CZB-273S-P1
Stanford ref. no. S22-487

Researchers at Stanford University have developed a new approach for proximity labeling via optogenetic control.